Drugmakers who do not want a repeat of the Sovaldi pricing uproar are hoping that a better introduction of their drugs will provide a greater understanding and acceptance of their price tags. Take, for example, Biogen’s developing drug to SLOW (not cure) Alzheimer’s progression, which is looking at a $10,000 per month price tag…. for the remainder of the patient’s life. Read more here. (Source: Bloomberg Business, 5/4/15)
You are here: / / Can Drugmakers Avoid Another ‘Sovaldi Backlash’ and Still Keep Raising Prices?